TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02763917

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Air Purifier
Description: Two portable air purifiers containing HEPA filters will be placed in the bedroom and room where the participant reports spending the most time. Participants will be instructed to run the air purifiers continually. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Air Purifier
Description: Homes in the control group will receive placebo air purifiers that have the internal air filters removed, but which will run normally. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight. At the end of the study, participants in the control group will receive active air purifiers. A control group is needed to ensure that reduced pollutant levels and health effects are not due to temporal trends and 'placebo effects' of being enrolled in an intervention trial. Participants will be informed that being in the study does not prevent them from purchasing and using air cleaners during the study period.
Study: NCT03250247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stents
Description: US-guided puncture of vein, fluoroscopic monitoring of catheter/guidewire manipulations, baseline venogram of CFV through infrarenal IVC.~Iliac vein should be pre-dilated to at least 12 mm. Bare, self-expanding stents made of elgiloy or nitinol legally marketed in the US for any indication and that are at least 12 mm in diameter should be used to recanalize the entire diseased segment of vein.~The use of devices \> 14 mm is highly recommended for the iliac vein and dilated to at least 14 mm, unless compelling patient factors dictates dilatation to a smaller diameter.~Balloon angioplasty of inflow veins.~After successful iliac vein recanalization, patients who continue to be symptomatic beyond 2 weeks follow-up and who have valvular reflux in GSV, accessory GSV, anterolateral thigh circumflex, and/or SSV should be offered endovenous ablation.~Any FDA-approved method may be used including radiofrequency or laser ablation, sclerotherapy or pharmacomechanical ablation.
Study: NCT03662035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib~Patients with advanced pancreatic cancer after failure of first-line chemotherapy will receive Apatinib (500mg/d, orally) 30 minutes after meal with warm water.Take 21 days as a cycle, patients will receive this treatment until they have got disease progressed. Dose adjustment: with 3/4 level of adverse reactions, the dose should be lowered to 250 mg/d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1~Patients will receive S-1 (60mg/d for BSA\<1.25m2, 80mg/d for 1.25\<BSA\<1.5m2, and 100mg for BSA \>1.5m2, orally) twice a day, once after breakfast and once after dinner, for 14 days, 7 days for suspension and 21 days as one cycle.
Study: NCT04585243

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evalyn Brush
Description: The Evalyn Brush is a self-sampling kit that can be used to collect a sample to screen for HPV/Cervical cancer at home.
Study: NCT04279990

Intervention type: OTHER
Intervention: No intervention: assessment of GI function
Description: Gastrointestinal function is assessed by the intragastric pressure measurement by a high resolution manometry. This is an examination test considered standard of care for the diagnosis of functional dyspepsia in the university hospital of leuven.~The joint hypermobility syndrome is assess by means of the Brighton criteria.

Intervention type: OTHER
Intervention: No intervention: assessment of GI function
Description: Gastrointestinal function is assessed by the intragastric pressure measurement by a high resolution manometry. This is an examination test considered standard of care for the diagnosis of functional dyspepsia in the university hospital of leuven.~The joint hypermobility syndrome is assess by means of the Brighton criteria.

Intervention type: OTHER
Intervention: No intervention: assessment of GI function
Description: Gastrointestinal function is assessed by the intragastric pressure measurement by a high resolution manometry. This is an examination test considered standard of care for the diagnosis of functional dyspepsia in the university hospital of leuven.~The joint hypermobility syndrome is assess by means of the Brighton criteria.
Study: NCT00627926

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated Interferon Alfa 2a
Description: subcutaneous injection, 180 micrograms once per week
Study: NCT01389089

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A-V Impulse compression
Description: A-V Impulse compression dosage: 130mmHg exerted to the sole of the foot for one second, every twenty second.
Study: NCT00627926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa 2a
Description: subcutaneous injection, 180 micrograms once per week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa 2a
Description: subcutaneous injection, 180 micrograms once per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: 375 mg tablets administered orally every 8 hours at a dose of 750 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: 375 mg tablets administered orally every 8 hours at a dose of 750 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: 200 mg tablets administered orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing ≥75 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg tablets administered orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing ≥75 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg tablets administered orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing ≥75 kg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Telaprevir matching placebo
Study: NCT04533048

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MW33 injection
Description: a recombinant fully human antibody to coronavirus

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MW33 injection placebo
Description: Placebo
Study: NCT00627926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Telaprevir matching placebo
Study: NCT00873067

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Additional Complex Fractionated Electrograms ablation
Description: Atrial fibrillation ablation with pulmonary vein ablation and roof line. In addition, complex fractionated atrial electrograms ablation will be performed, lasting at most 30 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard atrial fibrillation ablation procedure
Description: Standard procedure for persistent atrial fibrillation including circumferential pulmonary vein ablation and roof line, both being tested. No other lines or lesions will be performed.
Study: NCT02746094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8 bi-weekly LIESWT sessions
Description: LIESWT = Low-Intensity Extracorporeal Shock Wave Therapy~The treatment protocol consists of eight bi-weekly treatment sessions (weeks 0 ot 4). During each session 3600 shocks at 0.09 mJ/mm are applied. Shocks are applied to the penis shaft at the right corpus cavernosum and the left corpus cavernosum, and at the crura at the right crus and the left crus. 900 shocks are administered to each area. The treatment areas are the same for each session, so that at the end of the full treatment (8 sessions) each area will have received 7200 shocks at 0.09 mJ/mm.~In general, the patient is placed on an examination table. A series of focused shockwaves produced by the electromagnetic transducer are coupled to a patient's penile shaft and crura and are made to converge along the penis/crura volume. The operator controls treatment parameters including shockwave intensity and shockwave rate.~mJ = millijoule.
Study: NCT00288444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lonafarnib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lonafarnib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lonafarnib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lonafarnib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study: NCT04210843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ligelizumab
Description: For the first 12 weeks of treatment: i) participants transitioning from CQGE031C2302 (NCT03580369) and CQGE031C2303 (NCT03580356) previously treated with ligelizumab 72 mg LIVI s.c. Q4W were treated with the same dose regimen in a double-blind manner; ii) all other participants transitioning from CQGE031C2302 (NCT03580369) and CQGE031C2303 (NCT03580356) were treated with ligelizumab 120 mg LIVI s.c. Q4W in a double-blind manner; iii) participants transitioning from CQGE031C1301 (NCT03907878) and CQGE031C2202 (NCT03437278) were treated with ligelizumab 120 mg LIVI s.c. Q4W in an open-label manner.~Thereafter, all participants were switched to ligelizumab 120 mg s.c. PFS Q4W in an open-label manner and they were offered an opportunity to self-administer ligelizumab.~The longest possible treatment was 104 weeks, however this treatment might not be continuous and might span over a period of 156 weeks due to the possibility of entering the intervening observation period.
Study: NCT00288444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study: NCT00290654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen may be used postoperatively at the discretion of the treating physicians and patient

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy
Description: A standard lumpectomy will be performed with an attempt to remove at least 1 cm of gross margin around the DCIS.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: Treatment will be given in 10 fractions of 3.4 Gy per fraction twice a day, with a minimum of 6 hours between fractions. In general, brachytherapy will start between 2 - 5 days of implant. All treatments will be done using a commercially available HDR and 192Ir radioactive sources.
Study: NCT02343432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: Triamcinolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: Triamcinolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: Triamcinolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural Volume
Description: Epidural Volume

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural Volume
Description: Epidural Volume

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural Volume
Description: Epidural Volume

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine
Study: NCT03103217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief CBT for anxious pregnant women
Description: one off 3 hour session including psychoeducation, exploration of cognitions and experiential practice of behavioural techniques.
Study: NCT00647036

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isonitrogenous Vaminolact
Description: Isonitrogenous Vaminolact

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipeptiven (L-glutamine- Lalanine)
Description: 0.6g/kg/day
Study: NCT01675388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: Hypothermia to 33.5 deg C
Study: NCT02716922

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical cerclage
Description: Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix Cerclage type: McDonald Cerclage Suture: Permanent monofilament Pericerclage antibiotics: none Pericerclage tocolytics: none Bed rest: not recommended (in both groups)
Study: NCT03768921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP Titriation
Description: The alveolar recruitment maneuver PEEP reaches a maximum of 25 cmH2O, with recruitment being performed progressively, where the pressure variation is maintained at 15 cmH2O and the PEEP increase progressively occurs at 2 cmH2O every 2 minutes and Ventilatory mode with Controlled Pressure Ventilation. After the alveolar recruitment maneuver, the PEEP titration or determination will be performed, where the PEEP of 2 cmH2O will be reduced every 2 minutes and the variables after the alveolar recruitment maneuver and PEEP maintenance will be checked in the TIMPEL brand equipment at the point where the patient has better alveolar recruitment, with fewer alveolar collapsing points and pulmonary hyperdistension.
Study: NCT00548249

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Bicarbonate Solution
Description: Patients received 0 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soluble Ferric Pyrophosphate
Description: Patients received 5 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soluble Ferric Pyrophosphate
Description: Patients received 10 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soluble Ferric Pyrophosphate
Description: Patients received 12 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soluble Ferric Pyrophosphate
Description: Patients received 15 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
Study: NCT00490672

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No Active Intervention.
Description: Conventional Chronic Disease Management in Malaysia Primary Care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Based Multiple Risk Factor Intervention Strategies
Description: Multi-faceted Intervention in Chronic Diseases Management i.e. Hypertension, Diabetes Mellitus, Hyperlipidaemia involving Primary Health Care Physicians, Nurse Educators, Dieticians and Pharmacists.
Study: NCT04344522

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial keratoplasty DMEK
Description: DMEK : it involves separating the Descemet membrane from a corneal donor graft , doing a descematorhexis in the recepient cornea , loading and injection of the graft into the anterior chamber , unfolding and fixing the graft to the recepient cornea by intracameral air bubble.
Study: NCT02844777

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg applied once-daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% VDA-1102
Description: 200 mg applied once-daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% VDA-1102
Description: 200 mg applied once-daily for 28 days
Study: NCT02949245

Intervention type: PROCEDURE
Intervention: Interventions
Description: Procedure/Surgery: Routinely performed surgical correction of spinal deformity~Routinely performed surgical correction of spinal deformity
Study: NCT04771364

Intervention type: OTHER
Intervention: ASAP care's protocol
Description: Early geriatrician's advice, prefer locoregional anesthesia techniques where possible, early surgical therapy and medical adaptation on chronic patient's therapy (in particular with regard to sedative, anticholinergic and psychotropic drugs).
Study: NCT04344522

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IOL exchange
Description: IOL exchange : it involves performing a corneoscleral tunnel , freeing the AC IOL from any adhesions and explanting it through the tunnel , then implanting a posterior chamber PMMA lens or iris claw lens if there is no adequate capsular support.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IOL exchange
Description: IOL exchange : it involves performing a corneoscleral tunnel , freeing the AC IOL from any adhesions and explanting it through the tunnel , then implanting a posterior chamber PMMA lens or iris claw lens if there is no adequate capsular support.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iridoplasty
Description: iridoplasty : repairing any iris defect by using 10/0 prolene.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iridoplasty
Description: iridoplasty : repairing any iris defect by using 10/0 prolene.
Study: NCT00967005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N Acetyl Cysteine
Description: N-Acetyl Cysteine, 1200mg-3000mg each day for 24-weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: placebo control
Study: NCT04113057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Coaching
Description: In patients randomized to the remote coaching arm, study staff will provide feedback on home-based supplemental exercise based on heart rate and walking distance measurements from the LIVMOR health monitoring system.
Study: NCT02136368

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multi-modal exercise
Description: Community-based group exercise classes following Canadian Centre for Activity and Aging exercise guidelines. Exercise classes consist of 5 min warm-up, 20 min aerobic exercise, 5 min aerobic cool-down, 10 min full-body resistance exercise, 5 min stretching (total 45 min)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-modal exercise
Description: Community-based group exercise classes following Canadian Centre for Activity and Aging exercise guidelines. Exercise classes consist of 5 min warm-up, 20 min aerobic exercise, 5 min aerobic cool-down, 10 min full-body resistance exercise, 5 min stretching (total 45 min)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Motor Exercise
Description: Square Step Exercise involves mimicking a stepping pattern demonstrated by an instructor. The stepping patterns become progressively difficult and involve forward, backward, lateral and diagonal movements on a 250cm long mat with 25cm square grids (15 min).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance and range of motion exercises
Description: Community-based group exercise designed to improve balance and range of motion of the joints (15 min)
Study: NCT04344522

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inferior peripheral iridectomy
Description: Inferior peripheral iridectomy : performed by vannus scissor to avoid postoperative pupillary block due to the intracameral air .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inferior peripheral iridectomy
Description: Inferior peripheral iridectomy : performed by vannus scissor to avoid postoperative pupillary block due to the intracameral air .
Study: NCT04054674

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abutments with flat occlusal scheme preparation restored by lithium disilicate crowns
Description: Clinical trials lacks information about flat occlusal preparation design in case of endodontically treated teeth. Therefore, this is tested during preparation when compared to planer occlusal preparation while the final restoration in both arms is lithium disilicate (e.max) crowns.
Study: NCT05007171

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Very low calorie diet
Description: During 3 weeks in hospital patients will eat prepared very low calorie diet composed of 50-60% complex carbohydrates with low carbo-glycemic index, 20-25% proteins and 25-30% fat
Study: NCT02373423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advocacy
Description: See above for description
Study: NCT01608672

Intervention type: BIOLOGICAL
Intervention: botulinum toxin Type A
Description: botulinum toxin Type A (BOTOX®) treatment to glabellar lines as prescribed by the Investigator over at least 5 years.
Study: NCT02259699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: PCOA will be designed to accomplish 2 objectives: 1) it will educate patients and allow them to assimilate information about the differences in outcomes and survival between IP and IV therapies; and 2) it will help patients make the difficult trade-offs between these two treatment options.
Study: NCT03381859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
Description: Hepatitis C Virus direct-acting antiviral